SS-31 and Elamipretide: What the FDA Approval Actually Covers
Elamipretide, also called SS-31 in research, is the active ingredient in Forzinity, which received FDA accelerated approval in September 2025 for muscle strength in a defined Barth syndrome population. That approval does not establish general anti-aging benefits or approve separately sold SS-31 research materials.
Why does SS-31 research keep returning to cardiolipin?
Cardiolipin is a lipid associated with the inner mitochondrial membrane, where energy-producing machinery is organized. That location explains why SS-31 attracts interest beyond the familiar idea of a compound simply removing reactive oxygen species. Its experimental story concerns how a membrane environment influences energy transfer.
In a 2014 study, Birk and colleagues investigated interactions with cardiolipin-containing model membranes and isolated mitochondrial preparations. They reported effects on the cardiolipin–cytochrome c complex, including suppression of peroxidase activity and support for electron transfer and ATP production. These experiments connect a proposed molecular interaction with measurable bioenergetic behavior.
The distinction matters: showing an effect in a membrane preparation answers a mechanism question. It cannot tell us whether a person will walk farther, feel less tired or live longer.
Human tissue is an important step, but still a laboratory experiment
A 2019 study examined tissue from explanted failing and nonfailing human hearts. Elamipretide improved selected mitochondrial-function measurements in failing tissue; comparable effects were not observed in the nonfailing samples. The response depended on the condition of the tissue and the endpoint being measured.
This is stronger human biological context than a model membrane alone, but the experiment was performed outside the body. It did not assign living patients to a treatment and follow hospitalization, symptoms or survival. A headline containing “human heart” should therefore prompt a second question: was this a tissue experiment or a clinical trial?
Four studies, four different questions
The most useful way to read this literature is to keep the experimental setting beside the result. The rows below are not interchangeable demonstrations of a single universal benefit.
| Evidence | Setting and endpoint | What it can establish |
|---|---|---|
| Birk, 2014 | Model membranes and mitochondrial preparations | Mechanistic interaction and bioenergetic effects |
| Chatfield, 2019 | Explanted human heart tissue | Ex vivo mitochondrial responses |
| MMPOWER-3, 2023 | 218 people with primary mitochondrial myopathy | No improvement in the two primary 24-week outcomes |
| Forzinity label, 2025 | Small Barth syndrome study and extension | Narrow accelerated approval based on knee-strength findings |
What exactly did FDA approve?
On September 19, 2025, FDA granted accelerated approval to Forzinity for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. FDA required a subsequent randomized, placebo-controlled study to confirm that the observed knee-strength changes translate into patient benefit.
The prescribing information adds essential context. The randomized Barth study enrolled 12 participants and did not show superiority on its primary walking-distance and fatigue endpoints. Increased knee-extensor strength was observed during the open-label extension, not the randomized phase. The label identifies this strength measure as an intermediate clinical endpoint.
An extension can provide valuable longer-term observations, but it lacks the same concurrent blinded comparison. Reading the approval and its evidentiary limits together is more informative than treating either “approved” or “the trial failed” as the entire story.
Why the larger mitochondrial-myopathy trial still matters
MMPOWER-3 studied a different population: adults with genetically confirmed primary mitochondrial myopathy. Its 218 participants were randomized to elamipretide or placebo, and the principal assessments at 24 weeks were six-minute walking distance and patient-reported fatigue.
Neither primary endpoint improved significantly versus placebo. The estimated between-group walking-distance difference was −3.2 meters, with a 95% confidence interval from −18.7 to 12.3 meters. That finding does not establish an exercise benefit in this population.
There is no contradiction in a compound having a specific regulatory indication while a different disease trial is negative. Population, endpoint and study design define the claim. Substituting a broad phrase such as “mitochondrial optimization” erases those distinctions.
Why a research vial does not inherit a medicine’s approval
FDA approval evaluates a particular drug and its evidence for an intended population, with defined labeling and risk assessment. Matching an ingredient name is insufficient to show that another preparation is the approved product or equivalent to the clinical-trial supply.
For laboratory readers, molecular identity, experimental performance and regulatory status belong in separate columns. A research material may be relevant to a defined laboratory question without being a medicine. This article does not establish the identity, clinical equivalence or suitability for human use of any FSD material.
The next paper worth reading should answer a precise question
Look first for the model and the outcome: membrane interaction, respiration, ATP production, muscle strength or a patient-centered result. Then ask whether the control group and follow-up support that conclusion. An improvement in one measurement should not be silently expanded into improvement across all mitochondrial functions.
The most interesting next result is one that closes a specific evidence gap, especially the confirmatory Barth trial, rather than another repetition of the mechanism.
Common questions
Are SS-31 and elamipretide the same research compound?
SS-31 is a research name used for elamipretide. A shared molecular name does not establish that separately manufactured preparations are equivalent to Forzinity.
Is elamipretide FDA-approved in 2026?
Yes. The verified approval is Forzinity for muscle strength in Barth syndrome patients weighing at least 30 kg. It is accelerated approval with a required confirmatory study, not a general longevity approval.
Does research in human heart tissue prove a heart-failure treatment benefit?
No. The cited heart study tested explanted tissue. It measured mitochondrial responses outside the body, not clinical outcomes after treating patients.
Sources & scope
These references explain analytical and research principles. They do not certify FSD BIO LABS or provide evidence about a particular FSD batch.
- Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex (2014) — Birk et al. · British Journal of Pharmacology
Primary mechanistic experiments in model membranes and isolated mitochondria; supports cardiolipin interaction, cytochrome c behavior and bioenergetic readouts. Indexed full-text passages verified; not human efficacy evidence. - Elamipretide improves mitochondrial function in the failing human heart (2019) — Chatfield et al. · JACC: Basic to Translational Science
Primary ex vivo human-tissue study. Full text verified. Supports selected mitochondrial effects in explanted failing hearts, not treatment outcomes in living patients. - MMPOWER-3 randomized clinical trial (2023) — Karaa et al. · Neurology
Primary phase 3 trial, 218 participants with primary mitochondrial myopathy. Abstract and results verified; neither coprimary endpoint improved versus placebo at 24 weeks. - Forzinity prescribing information (2025) — U.S. Food and Drug Administration
Approved product label, especially indication and section 14. Verified the 12-participant Barth study, negative randomized primary endpoints, extension-period knee-strength findings, and accelerated-approval limitation. - FDA grants accelerated approval to first treatment for Barth syndrome — U.S. Food and Drug Administration
September 19, 2025 approval announcement, freshly checked October 20, 2026. Supports the specified Forzinity approval and required confirmatory randomized trial. - Development and approval process: drugs — U.S. Food and Drug Administration
Current FDA explanation of evidence review, labeling, intended population and benefit–risk assessment. Used to explain why an approval cannot be transferred to unrelated research materials.